Longitudinal PET-MR Study on Myelin Repair and Neuroinflammation in Multiple Sclerosis

The primary objective of this study is to investigate **remyelination** in **Multiple Sclerosis** (MS) using PET-MR imaging to assess individual profiles of myelin repair and the role of neuroinflammation. Understanding the dynamics of remyelination is clinically relevant as it may lead to improved therapeutic strategies for MS, potentially enhancing patient outcomes by promoting neural repair and reducing disability progression.

The clinical trial focuses on **remyelination in Multiple Sclerosis** and includes both male and female participants. The study population encompasses adults, as indicated by the age range category code "3," which typically refers to individuals aged 18 years and older. Participants are not drawn from a vulnerable population, ensuring a general representation of the adult demographic. The sponsor has not provided specific information regarding the total number of participants involved in the trial. The selection process for the trial population, as well as any lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Additionally, key inclusion or exclusion criteria have not been specified by the sponsor.

The clinical trial is designed to investigate **remyelination** in **multiple sclerosis** through a PET-MR longitudinal study. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the researchers know which participants belong to the control group or the experimental group. This design minimizes bias and enhances the reliability of the results. The trial commenced on January 24, 2022, and is projected to conclude by December 24, 2025, providing a comprehensive timeframe to assess the long-term effects and outcomes of the intervention.

Participants will undergo a series of study visits, beginning with an inclusion visit, which serves as a screening process to determine eligibility based on predefined criteria. Following successful inclusion, participants will attend regular follow-up visits, which are scheduled to monitor progress, assess the efficacy of the intervention, and ensure participant safety. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will culminate in an end-of-study visit, where final assessments are conducted, and participants are debriefed on the study's findings.

The expected length of participant involvement spans the entire duration of the trial, from the initial screening to the end-of-study visit. However, certain conditions may necessitate early termination from the study, such as adverse reactions, non-compliance with study protocols, or withdrawal of consent by the participant. These conditions are in place to prioritize participant safety and maintain the integrity of the study data. The trial is conducted in accordance with ethical guidelines and regulatory standards, ensuring that all procedures are scientifically sound and ethically justified.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **experimental medication** and any **non-experimental treatments** cannot be provided. The trial documentation should be consulted for comprehensive information regarding the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized under phase 5, indicating a focus on post-marketing surveillance to gather additional information on the drug's effectiveness and safety. The estimated recruitment start date is January 24, 2022, with an anticipated end date of December 24, 2025. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to determine the treatment's impact. The trial's duration and phase suggest a comprehensive approach to evaluating long-term outcomes and potential benefits in a real-world setting.